Tomsk scientists have created a new drug for cancer diagnosis

© Illustration RIA Novosti . Alina Polyanionic introduced as a protein, labeled with the isotope technetium-99, locates the cancer cellTomsk scientists have created a new drug for cancer diagnosis© Illustration RIA Novosti . Alina Polyanina

Scientists of Tomsk Polytechnic University, Tomsk research Institute of Oncology and Institute of Bioorganic chemistry Russian Academy of Sciences has established radiopharmaceuticals for the precise diagnosis of cancer on the basis of the isotope technetium-99. Autumn is scheduled to begin preclinical testing of the drug.

Technetium-99 is the most popular diagnostic radioisotope used in nuclear medicine. On its basis the radiopharmaceuticals that allow you to accurately diagnose lesions in almost all organs.For the isotope with a special molecular complex is attached to the molecule-vector — a protein, peptide, antibody. In human blood solution is injected radiopharmaceutical and it spreads throughout the body. On the basis of what molecules-vector made a drug depends on which organ or pathological lesion, he will accumulate (the technetium accumulates mainly in glandular tissue). So, the antibodies will tend to bind to cancer cells. Using a gamma camera, doctors can «monitor» the distribution of isotopes in the human body, to localize the position of the tumor and to get an idea of its size and prevalence. The radionuclide technetium-99 loses half its activity after 6 hours and excreted from the human body in the period from 1.5 to 22 days depending on the administered dose.

CC BY-SA 3.0 / CJSC «Pharm-Sintez» / So on the screen of the scanner displays the distribution of radiopharmaceutical «Resoscan» on the basis of technetium-99 in the body intended to diagnose pathologies of the skeleton. In lesions of the radiopharmaceutical accumulates in large quantities and therefore these areas appear brighter. Tomsk scientists have created a new drug for cancer diagnosisCC BY-SA 3.0 / CJSC «Pharm-Sintez» / So on the screen of the scanner displays the distribution of radiopharmaceutical «Resoscan» on the basis of technetium-99 in the body intended to diagnose pathologies of the skeleton. In lesions of the radiopharmaceutical accumulates in large quantities and therefore these areas appear brighter. The principle of diagnostics head of Department of technology of organic substances and polymer materials TPU Mekhman Yusubov explains:

«Cancer cells have a «lock” in the form of receptors, and the protein in the preparation is the key to the receptors. So the key is not to lose in the mass of other similar keys, it is necessary to mark. This requires chelates. This marker absorb an isotope of technetium, which is easily fixed with gamma camera. Such a structure of the radiopharmaceutical allows very accurately determine the size of the tumor and its location. This is particularly important in the diagnosis of metastatic cancer, when cancer cells are «weeded out» from the primary tumor and affect other organs.»

Developed in TPU the radiopharmaceutical has a complex structure. It is based on skeleton protein, DARPin, which is the most effective in the diagnosis of socially important oncological diseases such as colorectal cancer, breast cancer, lung cancer, prostate cancer, squamous tumors of the head and neck, kidney cancer, ovarian cancer, etc. is attached To protein chelate complex that binds a protein with a radioactive isotope technetium-99.

© Photo : Press service of Usabecause the Department of technology of organic substances and polymer materials of Tomsk Polytechnic University Mekhman Yusubov at the laboratoryTomsk scientists have created a new drug for cancer diagnosis© Photo : Press service of Usabecause the Department of technology of organic substances and polymer materials of Tomsk Polytechnic University Mekhman Yusubov at the lab

«The principal novelty of our approach is the development of a new method of obtaining a chelate complex with the use of commercially available domestic ingredients. This approach is protected by patents of Russia, — says Mekhman Yusubov. — Created RFP will be used not only for diagnostics but also in therapy of cancer. To do this we need to replace the diagnostic radionuclide is technetium-99m on the therapeutic radionuclide rhenium-188/186». In the TPU it is expected that if the preclinical studies of the drug will begin this year, should be completed in 2020.

Source